BioSpace News Archive

BeiGene, a global announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor BRUKINSA® as a treatment for adult patients with Waldenström’s macroglobulinemia.

GenesisCare announced the opening of its new Sunnyvale Women’s Center with patient-friendly facilities and an experienced clinical team to this new site to provide Dallas-area residents with end-to-end, multidisciplinary breast healthcare.

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), today announced the appointment of biotech executive Bettina M. Cockroft, M.D., senior vice president and chief medical officer of Sangamo Therapeutics, Inc., to the company’s board of directors.

ChromaDex Corp. announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners.

Alpha Tau Medical Ltd. announced today that it has signed a sponsored research agreement with investigators at The University of Texas MD Anderson Cancer Center (“MD Anderson”) to evaluate potential immune stimulation by combining Alpha DaRT™ with DNA-repair inhibitors and immune checkpoint inhibitors for the treatment of breast tumors.

NovaBay® Pharmaceuticals, Inc. announces that its Special Meeting of Stockholders held on December 17, 2021, as adjourned to and reconvened on January 14, 2022, has been further adjourned until January 31, 2022 at 11:00 a.m. Pacific time.

Ra Medical Systems, Inc. (NYSE American: RMED) announces that Chief Executive Officer Will McGuire has issued the following Letter to Stockholders.

NovaBay ® Pharmaceuticals, Inc. announces its commitment to donate 2.5 million KN95 protective masks to schools, youth groups and other charitable organizations.

Arecor Therapeutics plc provides a business update and announces that its preliminary results for the 12 months ended 31 December 2021 will be issued during the week commencing 25 April 2022.

Senhwa Biosciences, Inc. announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients with Biliary Tract Cancer.